OncoMed reports its first quarterly results since its July IPO; net losses widen

OncoMed (OMED +1.5%) moves up after reporting its first results since going public in July.

Q2 net losses widened to $9.6M from $3.8M for the year ago period, mainly because of the timing of a $5M milestone payment in the same quarter last year.

Collaboration revenues declined to $2.9M, compared to $7.5M for Q212.

The company received a $10M milestone payment in August, related to the Phase I dose escalation in its vantictumab program, part of its collaboration with Bayer Pharma AG.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs